Neoadjuvant docetaxel, oxaliplatin and S-1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902): protocol of a multi-center, phase II study

Peer Review reports

Original Submission
26 Nov 2021	Submitted	Original manuscript
29 Apr 2022	Reviewed	Reviewer Report - Stefano Rausei
21 May 2022	Reviewed	Reviewer Report
1 Jun 2022	Reviewed	Reviewer Report - Anne Müller
11 Jun 2022	Author responded	Author comments - Shunji Endo
Resubmission - Version 2
11 Jun 2022	Submitted	Manuscript version 2
2 Jul 2022	Author responded	Author comments - Shunji Endo
Resubmission - Version 3
2 Jul 2022	Submitted	Manuscript version 3
Publishing
13 Jul 2022	Editorially accepted
23 Jul 2022	Article published	10.1186/s12885-022-09890-w

Back to article page